Hi {{lead.First Name:default=edit me}},
You can leverage our 70,000+ research-ready participant network to obtain leukocyte-enriched apheresis products (leukopaks) from patients with confirmed disease or healthy donors. Customers tell us leukopaks are a game changer for their research by:
- Improving the accuracy of process development parameters
- Reducing variability among donor PBMCs
- Addressing rare cell abundance issues
How would up to 10 billion PBMCs from a single donor–plus clinical annotation, HLA typing, demographics, and test results–bolster your therapy development program?
Please check out our leukopaks page to learn how you can leverage our unique patient-centric approach to biospecimen procurement or hit reply to contact me directly.
Warm regards,